Title:
MODIFICATION OF T CELLS
Document Type and Number:
WIPO Patent Application WO/2023/178358
Kind Code:
A3
Abstract:
Modified immune cells are provided, the modified immune cells expressing a heterologous polynucleotide comprising a nucleotide sequence encoding a function (e.g., at least one of persistence, proliferation, or cytotoxicity) booster, e.g., an apoptosis inhibitor. In one aspect, the modified T cells further comprise a chimeric antigen receptor. Methods, kits, and components for making and using the modified immune cells are also provided.
Inventors:
SHUI YIFANG (US)
MINSHULL JEREMY (US)
LEE MAGGIE (US)
SHI FENG (US)
MINSHULL JEREMY (US)
LEE MAGGIE (US)
SHI FENG (US)
Application Number:
PCT/US2023/064729
Publication Date:
December 14, 2023
Filing Date:
March 20, 2023
Export Citation:
Assignee:
DNA TWOPOINTO INC (US)
MASSACHUSETTS GEN HOSPITAL (US)
MASSACHUSETTS GEN HOSPITAL (US)
International Classes:
C07K16/28; C07K14/47; C12N15/867; C12N5/0783
Domestic Patent References:
| WO2020163755A1 | 2020-08-13 |
Foreign References:
| US20200123254A1 | 2020-04-23 |
Attorney, Agent or Firm:
KERN, Benjamen, E. (US)
Download PDF:
Previous Patent: BISPECIFIC ANTIBODY FUSION MOLECULES AND METHODS OF USE THEREOF
Next Patent: BREWING SYSTEM
Next Patent: BREWING SYSTEM